These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 25382372)

  • 1. The potential of circulating nucleic acids as components of companion diagnostics for predicting and monitoring chemotherapy response.
    Schwarzenbach H
    Expert Rev Mol Diagn; 2015 Feb; 15(2):267-75. PubMed ID: 25382372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic and circulating biomarkers: future analytes for liquid biopsies.
    Razvi E
    Epigenomics; 2013 Dec; 5(6):615-7. PubMed ID: 24283876
    [No Abstract]   [Full Text] [Related]  

  • 3. [Advances in research on circulating nucleic acids as diagnostic markers for cancer].
    Jing RR; Wang HM; Wang ZW
    Zhonghua Zhong Liu Za Zhi; 2011 Dec; 33(12):881-4. PubMed ID: 22340094
    [No Abstract]   [Full Text] [Related]  

  • 4. Liquid Profiling of Circulating Nucleic Acids as a Novel Tool for the Management of Cancer Patients.
    Holdenrieder S
    Adv Exp Med Biol; 2016; 924():53-60. PubMed ID: 27753019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Personalized oncology: recent advances and future challenges.
    Kalia M
    Metabolism; 2013 Jan; 62 Suppl 1():S11-4. PubMed ID: 22999010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating Biomarkers for Prediction of Treatment Response.
    Cappelletti V; Appierto V; Tiberio P; Fina E; Callari M; Daidone MG
    J Natl Cancer Inst Monogr; 2015 May; 2015(51):60-3. PubMed ID: 26063889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical relevance of circulating, exosomal miRNAs as biomarkers for cancer.
    Schwarzenbach H
    Expert Rev Mol Diagn; 2015; 15(9):1159-69. PubMed ID: 26202667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating tumour-derived nucleic acids in cancer patients: potential applications as tumour markers.
    Chan KC; Lo YM
    Br J Cancer; 2007 Mar; 96(5):681-5. PubMed ID: 17311021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing cancer with a blood draw.
    Azvolinsky A
    J Natl Cancer Inst; 2012 Dec; 104(23):1774-5. PubMed ID: 23213181
    [No Abstract]   [Full Text] [Related]  

  • 10. Diagnostic potential of circulating nucleic acids for oncology.
    Goessl C
    Expert Rev Mol Diagn; 2003 Jul; 3(4):431-42. PubMed ID: 12877383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic alterations of tumor marker microRNAs: towards new cancer therapies.
    Wei J; Xie L; Taron M; Rosell R; Liu B
    Drug News Perspect; 2010 Dec; 23(10):655-61. PubMed ID: 21180651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic alterations in cancer and personalized cancer treatment.
    Miozzo M; Vaira V; Sirchia SM
    Future Oncol; 2015; 11(2):333-48. PubMed ID: 25591842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The evolving potential of companion diagnostics.
    Khoury JD
    Scand J Clin Lab Invest Suppl; 2016; 245():S22-5. PubMed ID: 27433788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Free circulating nucleic acids in plasma and serum (CNAPS) -- Useful for the detection of lung cancer patients?
    Fleischhacker M; Schmidt B
    Cancer Biomark; 2010; 6(3-4):211-9. PubMed ID: 20660966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic profiling joins personalized cancer medicine.
    Heyn H; Méndez-González J; Esteller M
    Expert Rev Mol Diagn; 2013 Jun; 13(5):473-9. PubMed ID: 23782254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monitoring tumor-derived cell-free DNA in patients with solid tumors: clinical perspectives and research opportunities.
    Esposito A; Bardelli A; Criscitiello C; Colombo N; Gelao L; Fumagalli L; Minchella I; Locatelli M; Goldhirsch A; Curigliano G
    Cancer Treat Rev; 2014 Jun; 40(5):648-55. PubMed ID: 24184333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Making personalized cancer medicine a reality: challenges and opportunities in the development of biomarkers and companion diagnostics.
    Parkinson DR; Johnson BE; Sledge GW
    Clin Cancer Res; 2012 Feb; 18(3):619-24. PubMed ID: 22298894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The biggest challenges currently facing companion diagnostic advancement.
    Halim AB
    Expert Rev Mol Diagn; 2014 Jan; 14(1):27-35. PubMed ID: 24308333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Response predictive biomarkers to targeted therapies in oncology].
    Harlé A; Merlin JL
    Ann Biol Clin (Paris); 2013 Nov; 71():89-97. PubMed ID: 24235332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Possibilities and limitations of stratified medicine based on biomarkers and targeted therapies in oncology].
    Ludwig WD
    Z Evid Fortbild Qual Gesundhwes; 2012; 106(1):11-22. PubMed ID: 22325103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.